Saturday, June 04, 2016 1:51:38 PM
The spending will come down since CLBS 20 was suspended. This was not realized in the last quarter ER. Operations related to rental space will also come down due to the closing of the Madison Ave space and consolidation out to NJ. Lexington Ave is still open and I would think that also will be moved out to NJ. Rental space in CA was sub leased to Ai Vita. Thats off the plate. The 7-8m quarter will be down to 5m IMO. Sanford is paying for the Lions share of Phase II study of CLBS03. There is no doubt there is a long road ahead. I share your concerns about non disclosure of royalty payments and other milestone payments.
Recent LSTA News
- Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc. • GlobeNewswire Inc. • 03/06/2026 11:15:05 PM
- Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide • GlobeNewswire Inc. • 01/27/2026 01:00:00 PM
- All-Cash Buyout Sparks Breakout Move in Biotech Name • AllPennyStocks.com • 01/21/2026 04:14:37 PM
- Lisata Therapeutics surges on Kuva Labs takeover proposal carrying hefty premium • IH Market News • 01/21/2026 03:41:11 PM
- Lisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender Offer • GlobeNewswire Inc. • 01/21/2026 12:00:00 PM
- Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update • GlobeNewswire Inc. • 11/06/2025 09:05:00 PM
- Lisata Therapeutics Wins 2025 BioTech Breakthrough Award for ‘Overall BioPharma Solution of the Year’ • GlobeNewswire Inc. • 11/06/2025 01:00:00 PM
- Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent • GlobeNewswire Inc. • 11/04/2025 09:00:00 PM
- Lisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025 • GlobeNewswire Inc. • 10/30/2025 12:00:00 PM
- Lisata Therapeutics to Present at LD Micro Main Event XIX • Newsfile • 10/13/2025 12:00:00 PM
- Lisata Therapeutics and Catalent Announce Global Antibody-Drug Conjugate (ADC) License Agreement • GlobeNewswire Inc. • 10/08/2025 12:30:00 PM
- Lisata Therapeutics Announces Encouraging Preliminary Results from the Pancreatic Cancer Cohort of the CENDIFOX Trial • GlobeNewswire Inc. • 09/29/2025 12:00:00 PM
- Lisata Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference • GlobeNewswire Inc. • 09/02/2025 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/07/2025 08:13:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/07/2025 08:09:29 PM
- Lisata Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/07/2025 08:05:00 PM
- Lisata Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update on Thursday, August 7, 2025 • GlobeNewswire Inc. • 07/31/2025 12:00:00 PM
- Lisata Therapeutics and WARPNINE Announce iLSTA Trial Enrollment Completion and Provide Preliminary Data Update • GlobeNewswire Inc. • 07/17/2025 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/15/2025 12:00:44 PM
- Lisata Therapeutics Expands Intellectual Property Portfolio with New Composition of Matter Patent for Certepetide • GlobeNewswire Inc. • 07/15/2025 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/26/2025 12:38:40 PM
- Positive Preliminary Cohort B Results from the AGITG-led ASCEND Trial to be Presented at ESMO GI Evaluating Lisata’s Certepetide in Combination with Standard-of-Care Chemotherapy in Metastatic Pancreatic Cancer • GlobeNewswire Inc. • 06/26/2025 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/17/2025 01:13:57 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/13/2025 08:02:11 PM
- Lisata Therapeutics to Present at the 2025 BIO International Convention • GlobeNewswire Inc. • 06/11/2025 12:30:00 PM
